Zobrazeno 1 - 7
of 7
pro vyhledávání: '"V P, Bykerk"'
Autor:
L. Ellingwood, O. Schieir, M. F. Valois, S. J. Bartlett, L. Bessette, G. Boire, G. Hazlewood, C. Hitchon, E. C. Keystone, D. Tin, C. Thorne, V. P. Bykerk, J. E. Pope, on behalf of CATCH Investigators
Publikováno v:
ACR Open Rheumatology, Vol 1, Iss 10, Pp 614-619 (2019)
Background This multicenter incident cohort aimed to characterize how often early rheumatoid arthritis (ERA) patients self‐report episodic joint inflammation (palindromic rheumatism) preceding ERA diagnosis and which characteristics differentiate t
Externí odkaz:
https://doaj.org/article/880d4e39a61b487a84120f1eb6ed5131
Autor:
B. Kuriya, O. Schieir, M. F. Valois, J. E. Pope, G. Boire, L. Bessette, G. Hazlewood, J. C. Thorne, D. Tin, C. Hitchon, S.J. Bartlett, E. C. Keystone, V. P. Bykerk, L. Barra, on behalf of CATCH investigators
Publikováno v:
ACR Open Rheumatology, Vol 1, Iss 9, Pp 535-541 (2019)
Objective Metabolic syndrome (MetS) prevalence in early rheumatoid arthritis (ERA) is conflicting. The impact of sex, including menopause, has not been described. We estimated the prevalence and factors associated with MetS in men and women with ERA.
Externí odkaz:
https://doaj.org/article/1473bced22504520ab94150f50137f89
Autor:
J R, Curtis, S, Yang, L, Chen, J E, Pope, E C, Keystone, B, Haraoui, G, Boire, J C, Thorne, D, Tin, C A, Hitchon, C O, Bingham, V P, Bykerk
Publikováno v:
Arthritis careresearch. 67(10)
Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasingly used. The minimum clinically important differences (MCID) for some measures, such as the Clinical Disease Activity Index (CDAI), have not been well-defined in
Publikováno v:
Clinical and experimental rheumatology. 21(5 Suppl 31)
Data has been generated that infliximab may be more effective when initiated earlier in the course of disease. A subset analysis of the Attract trial has demonstrated better efficacy of infliximab in reducing joint damage in an early rheumatoid arthr
Publikováno v:
Clinical and experimental rheumatology. 21(5 Suppl 31)
Adalimumab, a recent addition to the therapeutic armamentarium in rheumatoid arthritis (RA), has been evaluated in patients with early RA. The DE019 study, a double blind randomized placebo controlled trial of adalimumab given 20 mg once a week or 40
Autor:
S, Carette, M J, Bell, W J, Reynolds, B, Haraoui, G A, McCain, V P, Bykerk, S M, Edworthy, M, Baron, B E, Koehler, A G, Fam
Publikováno v:
Arthritis and rheumatism. 37(1)
To compare the relative efficacy and tolerability of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia, and to identify predictors of response to amitriptyline and cyclobenzaprine.Two hundred eight patients who fulfilled th
Autor:
V P, Bykerk, H, Tannenbaum
Publikováno v:
The Journal of rheumatology. 13(3)
We describe a case of monoarthritis in an Inuit seal hunter which progressed to joint destruction of the distal interphalangeal joint despite early and aggressive sequential antibiotic therapy with ampicillin, cloxacillin and penicillin G. In retrosp